Awakn Life Sciences Corp.

CNSX:AWKN Stock Report

Market Cap: CA$4.6m

Awakn Life Sciences Valuation

Is AWKN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AWKN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AWKN (CA$0.12) is trading below our estimate of fair value (CA$7.65)

Significantly Below Fair Value: AWKN is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AWKN?

Key metric: As AWKN barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for AWKN. This is calculated by dividing AWKN's market cap by their current book value.
What is AWKN's PB Ratio?
PB Ratio-3.2x
Book-CA$1.56m
Market CapCA$4.58m

Price to Book Ratio vs Peers

How does AWKN's PB Ratio compare to its peers?

The above table shows the PB ratio for AWKN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4x
QPT Quest PharmaTech
0.3xn/aCA$5.1m
RKV Rakovina Therapeutics
1.3xn/aCA$5.0m
TELO Telo Genomics
13.9xn/aCA$8.9m
MPH Medicure
0.5xn/aCA$9.2m
AWKN Awakn Life Sciences
n/an/aCA$4.6m

Price-To-Book vs Peers: AWKN has negative equity and a Price-To-Book Ratio (-3.2x) compared to the peer average (4x).

Price to Book Ratio vs Industry

How does AWKN's PB Ratio compare vs other companies in the CA Biotechs Industry?

2 CompaniesPrice / BookEstimated GrowthMarket Cap
QPT Quest PharmaTech
0.3xn/aUS$3.63m
CURE.X Biocure Technology
0.2xn/aUS$224.17k
No more companies available in this PB range
AWKN is unprofitableIndustry Avg. 2.6xNo. of Companies2PB01.22.43.64.86+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: AWKN has negative equity and a Price-To-Book Ratio (-3.2x) compared to the Canadian Biotechs industry average (2.6x).

Price to Book Ratio vs Fair Ratio

What is AWKN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AWKN PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-3.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate AWKN's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Verano Holdings

CA$765.1m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$2.02

7D

-14.8%

1Y

-65.2%

Fennec Pharmaceuticals

US$129.5m

Operates as a biopharmaceutical company in the United States.

FRX

US$7.35

7D

30.1%

1Y

-38.9%

Cresco Labs

CA$709.6m

Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States.

CL

CA$1.51

7D

-23.4%

1Y

-32.3%